Cyclical etidronate in the prevention of bone loss in corticosteroid-treated primary biliary cirrhosis. A prospective, controlled pilot study

Journal of Hepatology

Volumn 26, Issue 2, 1997, Pages 325-330

  Wolfhagen, Frank H J ^b   Van Buuren, Henk R ^b   Den Ouden, Janny W ^b   Hop, Wim C J ^a   Van Leeuwen, Johannes P T M ^b   Schalm, Solko W ^b   Pols, Huib A P ^b  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b NONE

Author keywords

bisphosphonates; bone mass; corticosteroids; liver disease

Indexed keywords

CALCIUM CARBONATE; CORTICOSTEROID; ETIDRONIC ACID; PREDNISONE; URSODEOXYCHOLIC ACID;

ADULT; AGED; ARTICLE; BILIARY CIRRHOSIS; BONE ATROPHY; BONE DENSITY; BONE MASS; BONE MINERAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MALE; OSTEOLYSIS; PRIORITY JOURNAL; X RAY;

EID: 0031054020     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(97)80048-7     Document Type: Article

References (34)

1. Sherlock S, Dooley J. 9th edn. Diseases of the Liver and Biliary System. 1994;237-248 Blackwell Scientific Publications, London.
2. Eastell R, Dickson ER, Hodgson SF, Wiesner RH, Porayko MK, Wahner HW, Cedel SL, Riggs BL, Krom RAF. Rates of vertebral bone loss before and after liver transplantation in women with primary biliary cirrhosis. Hepatology. 14:1991;296-300.
3. Hodgson SF, Dickson ER, Eastell R, Eriksen EF, Bryant SC, Riggs BL. Rates of cancellous bone remodelling and turnover in osteopenia associated with primary biliary cirrhosis. Bone. 14:1993;819-827.
4. Wolfhagen FHJ, Van Buuren HR, Schalm SW. Combined treatment with ursodeoxycholic acid and prednisone in primary biliary cirrhosis. Neth J Med. 44:1994;84-90.
5. Wolfhagen FHJ, Van Buuren HR, Van Berge Henegouwen GP, Van Hattum J, Den Ouden JW, Kerbert MJ, Smit AM. A randomized, placebo-controlled trial with prednisone/azathioprine in addition to ursodeoxycholic acid in primary biliary cirrhosis [Abstract]. J Hepatol. 21:1994;S49.
6. Mitchison HC, Bassendine MF, Malcolm AJ, Watson AJ, Record CO, James OFW. A pilot, double-blind controlled 1-year trial of prednisolone treatment in primary biliary cirrhosis: hepatic improvement but greater bone loss. Hepatology. 10:1989;420-429.
7. Mitchison HC, Palmer JM, Bassendine MF, Watson AJ, Record CO, James OFW. A controlled trial of prednisolone treatment in primary biliary cirrhosis; three year results. J Hepatol. 15:1992;336-344.
8. Meunier PJ. Is steroid-induced osteoporosis preventable? N Engl J Med. 328:1993;1781-1782.
9. Ott SM. Clinical effects of bisphosphonates in involutional osteoporosis. J Bone Min Res. 8:1993;S597-S606. (suppl. 2).
10. Storm T, Thamsborg G, Steiniche T, Genant HK, Sorensen OH. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med. 322:1990;1265-1271.
11. Watts NB, Harris ST, Genant HK, Wasnich RD, Miller PD, Jackson RD, Licata AA, Ross P, Woodson GC, Yanover MJ, Mysin J, Kohse L, Rao MB, Steiger P, Richmond B, Chesnut CH III. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med. 323:1990;73-79.
12. Harris ST, Watts NB, Jackson RD, Genant HK, Wasnich RD, Ross P, Miller PD, Licata AA, Chesnut CH III. Four-year study of intermittent cyclic etidronate treatment of post-menopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. Am J Med. 95:1993;557-567.
13. for the Alendronate Phase III osteoporosis treatment study group Liberman UA, Weiss SR, Bröll J, Minne HW, Quan H, Bell NH, Rodrigues-Portales J, Downs RW, Dequeker J, Favus M, Seeman E, Recker RR, Capizzi T, Santora AC, Lombardi A, Shah RV, Hirsch LJ. Effect of oral alendronate on bone mineral density and the incidence of fractures in post-menopausal osteoporosis. N Engl J Med. 333:1995;1437-1443.
14. Reid IR, Alexander CJ, King AR, Ibbertson HK. Prevention of steroid induced osteoporosis with (3-amino-1-hydroxypropylididene)-,1-bisphosphonate (APD). Lancet. i:1988;143-146.
15. Adachi JD, Cranney A, Goldsmith CH, Bensen WG, Bianchi F, Cividino A, Craig GL, Kaminska E, Sebaldt RJ, Papaionnou A, Boratto M, Gordon M, Steele M. Intermittent cyclical therapy with etidronate in the prevention of corticosteroid induced bone loss. J Rheumatol. 21:1994;1922-1926.
16. Mulder H, Struys A. Intermittent cyclical etidronate in the prevention of corticosteroid-induced bone loss. Br J Rheumatol. 33:1994;348-350.
17. Diamond T, McGuigan L, Barbagallo S, Bryant C. Cyclical etidronate plus ergocalciferol prevents glucocorticoid-induced bone loss in postmenopausal women. Am J Med. 98:1995;459-463.
18. Struys A, Snelder AA, Mulder H. Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis. Am J Med. 99:1995;235-242.
19. Taal BG, Schalm SW, Ten Kate FWJ, Hermans J, Geertzen GM, Feltkamp BEW. Clinical diagnosis of primary biliary cirrhosis: a classification based on major and minor criteria. Hepato-gastroenterol. 30:1983;178-182.
20. Reid IA, Grey AB. Corticosteroid osteoporosis. Baillière's Clin Rheumatol. 7:1993;573-588.
21. Hodgson SF, Dickson ER, Wahner HW, Johnson KA, Mann KG, Riggs BL. Bone loss and reduced bone osteoblast function in primary biliary cirrhosis. Ann Intern Med. 103:1985;855-860.
22. Delmas PD. Biochemical markers of bone turnover. J Bone Min Res. 8:1993;S549-S555.
23. Gennari C, Vitelli R. Glucocorticoid-induced osteoporosis. Clin Rheum Dis. 12:1986;637-654.
24. Rosen H. Primary biliary cirrhosis and bone disease. Hepatology. 21:1995;253-255.
25. Van Berkum FNR, Beukers R, Birkenhäger JC, Kooij PPM, Schalm SW, Pols HAP. Bone mass in women with primary biliary cirrhosis; the relation with histological stage and use of corticosteroids. Gastroenterology. 99:1990;1134-1139.
26. Poupon RE, Balkau B, Eschwège E, Poupon R. A multicenter controlled trial of ursodiol for the treatment of primary biliary cirrhosis. N Engl J Med. 324:1991;1548-1554.
27. Stellon AJ, Davies A, Compston J, Williams R. Bone loss in autoimmune chronic active hepatitis on maintenance corticosteroid therapy. Gastroenterology. 89:1985;1078-1083.
28. Guañabens N, Parés A, Mariñoso L, Brancós MA, Piera C, Serrano S, Rivera F, Rodés J. Factors influencing the development of metabolic bone disease in primary biliary cirrhosis. Am J Gastroenterol. 85:1990;1356-1362.
29. Bonkovsky HL, Hawkins M, Steinberg K, Hersh T, Galambos JT, Henderson JM, Millikan WJ, Galloway JR. Prevalence and prediction of osteopenia in chronic liver disease. Hepatology. 12:1990;273-280.
30. Lindor KD, Janes CH, Crippin JS, Jorgensen RA, Dickson ER. Bone disease in primary biliary cirrhosis: does ursodeoxycholic acid make a difference. Hepatology. 21:1995;389-392.
31. Heaney RP. Interpreting trials of bone-active agents. Am J Med. 98:1995;329-330.
32. Locascio V, Bonucci E, Imbimbo B, Ballantani P, Adami S, Milani S, Tartarotti D, Dellarocca C. Bone loss in response to long term glucocorticoid therapy. Bone Miner. 8:1990;39-51.
33. Sambrook PN, Cohen ML, Eisman JA, Pocock NA, Champion GD, Yeates MG. Effects of low dose corticosteroids on bone mass in rheumatoid arthritis: a longitudinal study. Ann Rheum Dis. 48:1989;535-538.
34. Clements D, Compston JE, Rhodes J, Evans WD, Smith PM. Low dose corticosteroids in chronic active hepatitis do not adversely affect spinal bone. Eur J Gastroenterol Hepatol. 5:1993;543-547.